Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1359 of 5804
-
Tailored gut bypass could curb obesity and malnutrition risks
Disease control Recruiting nowObesity is a serious health problem worldwide and can lead to many diseases such as diabetes, high blood pressure, heart disease, and sleep apnea. When lifestyle changes and medications are not enough, metabolic and bariatric surgery (MBS) is currently the most effective and long…
Phase: NA • Sponsor: El-Sahel Teaching Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Brain zaps guided by MRI aim to quiet PTSD symptoms
Symptom relief Recruiting nowMAGNETS is a prospective, randomized, parallel-design, sham-controlled clinical trial of accelerated, functional magnetic resonance imaging (fMRI)-guided intermittent theta burst stimulation (iTBS) to the right dorsolateral prefrontal cortex (dlPFC) for chronic symptoms of posttr…
Phase: NA • Sponsor: University of New Mexico • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New PET tracer could spare prostate cancer patients from repeated biopsies
Diagnosis Recruiting nowThe goal of this clinical trial is to test if the experimental agent accurately determines the aggressiveness of prostate cancer (biopsy-verified ISUP grade). The aim is that the diagnostic PET imaging agent may be used as an alternative or supplement to biopsies in the monitorin…
Phase: PHASE2 • Sponsor: Curasight • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Can surgery boost Radiation's punch against gut and pancreatic tumors?
Disease control Recruiting nowThis phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1 or 2, somatostatin receptor (SSTR) positive, gastr…
Phase: PHASE4 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo cuts chemo nausea in half for gynecologic cancer patients
Symptom relief CompletedTo determine the best method to prevent CINV caused by TC regimen in patients with gynecological malignant tumor. Paclitaxel-carboplatin (TC) is the most widely used regimen for gynecologic malignancies, yet chemotherapy-induced nausea and vomiting (CINV) remain common and distr…
Phase: PHASE3 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Could a diabetes drug shield your brain after radiation?
Disease control Recruiting nowThis phase III trial evaluates whether patient care can be done remotely for patients having cranial (skull) radiation or who have previously had cranial radiation. In addition, this trial compares study outcomes between patients who get metformin and those who do not. Cranial ra…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Artificial intelligence could revolutionize ARDS diagnosis and treatment
Diagnosis CompletedBy using multi-center chest CT data, an intelligent assessment model for the severity of ARDS was constructed. Based on CT quantitative features and clinical characteristics, a prediction model for short-term critical events (such as mechanical ventilation decisions, prone positi…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
Immune cells injected into brain tumors: a new hope for kids?
Disease control TerminatedThis phase I trial tests the safety, side effects, and best dose of ex vivo expanded natural killer cells in treating patients with cancerous (malignant) tumors affecting the upper part of the brain (supratentorial) that have come back (recurrent) or that are growing, spreading, …
Phase: PHASE1 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug AMG 732 aims to reduce eye bulging in thyroid eye disease
Disease control Recruiting nowThe primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) afte…
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New MRI-Guided radiation aims to zap sarcomas with pinpoint accuracy
Disease control Recruiting nowRecent advances in radiation treatment have allowed for higher doses per treatment to be delivered safely. This study plans to use an MRI-guided linear accelerator to deliver the radiation treatment to ensure that the radiation dose is administered to the cancerous tumor, not the…
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can lower doses of ibrutinib still control CLL? new trial aims to find out
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New filter may improve survival in pneumonia-related kidney failure
Disease control Recruiting nowThe purpose of this study aimed to compare the efficacy of Oxiris (Baxter) and M100 filters on IL-6 as primary outcomes and other blood cell counts, blood biochemistry (serum urea, creatinine, potassium, sodium), inflammation indicators (CRP, PCT), as secondary outcomes and safet…
Phase: NA • Sponsor: Mohd Zulfakar Mazlan, MBBS • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control OngoingThe purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage …
Phase: PHASE1 • Sponsor: Enliven Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo offers hope for tough blood cancers
Disease control Recruiting nowThe purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with rel…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Warm during surgery? new trial tests if temperature control boosts survival in older cancer patients
Disease control Recruiting nowIntraoperative hypothermia is common in patients having major surgery and the compliance with intraoperative temperature monitoring and management remains poor. Studies suggest that intraoperative hypothermia is an important risk factor of postoperative delirium, which is associa…
Phase: NA • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat leukemia? early trial launches
Disease control Recruiting nowThis is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 and spliceosome mutated Relapsed or Refractory Acute Myeloid Leukemia
Phase: PHASE1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for hard-to-treat lymphoma: experimental drug enters human testing
Disease control OngoingThe main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation), to further assess the safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion).
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New liquid embolic agent could shrink dangerous brain malformations
Disease control Recruiting nowThis study is designed as a prospective, multi-center, open-label, non-inferiority, randomized controlled clinical trial. The control device is Onyx Liquid Embolic System marketed by Micro Therapeutics Inc. DBA ev3 Neurovascular (NMPA (J) 20173136690). According to the inclusion …
Phase: NA • Sponsor: MicroPort NeuroTech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can antibodies keep HIV in check without daily pills?
Disease control OngoingThe main purpose of this study is to see if it is safe to give the study antibodies (3BNC117-LS-J and 10-1074-LS-J) by intravenous infusion to people with HIV (PWH), and to see if they cause any side effects. In addition, to see how the study antibodies affect the level of HIV in…
Phase: PHASE1 • Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New depression pill shows promise in Mid-Stage trial
Symptom relief CompletedThe purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Phase: PHASE2 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC